Page last updated: 2024-08-23

paclitaxel and Follicular Thyroid Carcinoma

paclitaxel has been researched along with Follicular Thyroid Carcinoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bockisch, A; Dralle, H; Kegel, T; Mann, K; Matuszczyk, A; Petersenn, S; Schmoll, HJ; Voigt, W1
Santarpia, L; Sarlis, NJ; Sherman, SI; Skarulis, MC; Tulloch-Reid, M1
Cignarelli, M; Fabiano, A; La Macchia, O; Landriscina, M; Maddalena, F; Piscazzi, A1
Kurebayashi, J; Namba, H; Pushkarev, VM; Saenko, VA; Starenki, DV; Tronko, MD; Yamashita, S1
Bekele, BN; Bucana, CD; Fidler, IJ; Hawthorne, VS; Jasser, SA; Kim, SJ; Mandal, M; Myers, JN; Park, YW; Yazici, YD; Yigitbasi, OG; Younes, MN1
El-Naggar, AK; Jasser, SA; Kim, S; Myers, JN; Yazici, YD; Younes, MN1
Fusco, A; Portella, G; Scala, S; Vecchio, G; Vitagliano, D1

Trials

1 trial(s) available for paclitaxel and Follicular Thyroid Carcinoma

ArticleYear
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:1

    Topics: Adenocarcinoma, Follicular; Adult; Aged; Carcinoma, Medullary; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thyroid Neoplasms

2010

Other Studies

6 other study(ies) available for paclitaxel and Follicular Thyroid Carcinoma

ArticleYear
Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.
    Anticancer research, 2009, Volume: 29, Issue:11

    Topics: Adenocarcinoma, Follicular; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Thyroid Neoplasms

2009
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.
    Anticancer research, 2010, Volume: 30, Issue:2

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thyroid Neoplasms; Tumor Cells, Cultured

2010
Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells.
    Endocrinology, 2004, Volume: 145, Issue:7

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Cell Death; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survivin; Thyroid Neoplasms; X-Linked Inhibitor of Apoptosis Protein

2004
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Cancer research, 2005, Jun-01, Volume: 65, Issue:11

    Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2

2005
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1

    Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Predictive Value of Tests; Prognosis; Purines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2006
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:6

    Topics: Adenocarcinoma, Follicular; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinogenicity Tests; Carcinoma; Carcinoma, Papillary; Cell Death; Defective Viruses; Doxorubicin; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

2002